Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics
Arielle Mendel, Sasha Bernatsky, Anca Askanase, Sang‐Cheol Bae, Ann E. Clarke, N. Costedoat‐Chalumeau, Dafna D. Gladman, Caroline Gordon, John G. Hanly, Søren Jacobsen, Kenneth Kalunian, Anselm Mak, Marta Mosca, Bernardo A. Pons‐Estel, Guillermo Ruiz‐Irastorza, Murray B. Urowitz, Évelyne Vinet
Topics & Concepts
HydroxychloroquineMedicinePandemicBelimumabSystemic lupus erythematosusCoronavirus disease 2019 (COVID-19)RheumatologyEconomic shortageLupus erythematosusIntensive care medicineImmunologyFamily medicineInternal medicineDiseaseAntibodyLinguisticsGovernment (linguistics)B-cell activating factorPhilosophyB cellInfectious disease (medical specialty)Systemic Lupus Erythematosus ResearchDrug-Induced Ocular ToxicityPeripheral Neuropathies and Disorders